Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis

Neuropediatrics

Volumn 42, Issue 1, 2011, Pages 7-12

  Kornek, Barbara ^a   Bernert, G ^b   Rostasy, K ^c   Mlczoch, E ^d   Feucht, M ^d   Prayer, D ^a   Vass, K ^a   Seidl, R ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Gottfried V Preyer's Hospital for Sick Children   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

children; mitoxantrone; multiple sclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONDANSETRON;

ADOLESCENT; ALOPECIA; ANEMIA; ARTICLE; CARDIOTOXICITY; CASE REPORT; CHILD; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INFECTION; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; MALE; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE;

ADOLESCENT; ANALGESICS; BLOOD CELL COUNT; CARDIOVASCULAR DISEASES; CHILD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 79955791751     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1275345     Document Type: Article

References (40)

1. Boggild M. Immunosuppression followed by immunomodulation. J Neurol Sci 2009 277 S50-S54
2. Boiko A, Vorobeychik G, Paty D. etal and the UBC MS Clinic Neurologists Early onset multiple sclerosis: A longitudinal study. Neurology 2002 59 1006-1010
3. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009 30 S155-S158
4. Dörr J, Bitsch A, Schmailzl KJ et al,. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009 73 991-993
5. Gatta G, Capocaccia R, Coleman MP et al,. Childhood cancer survival in Europe and the United States. Cancer 2002 95 1767-1772
6. Ghezzi A, Banwell B, Boiko A et al,. The management of MS in children. A European view. Mult Scler 2010 Aug 4. Epub ahead of print
7. Ghezzi A, Pozzilli C, Grimaldi LME et al,. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010 75 912-917
8. Goffette S, van Pesch V, Vanoverschelde JL et al,. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005 252 1217-1222 (Pubitemid 41443622)
9. Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for two years. Neurology 1990 40 S261
10. Gorman M, Healy B, Polgar-Turcsanyi M et al,. Increased relapse rate in pediatric-onset compared to adult-onset multiple sclerosis. Arch Neurol 2009 66 54-59
11. Hartung HP, Gonsette R, König N. etal and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 360 2018-2025 (Pubitemid 36026580)
12. Huppke P, Stark W, Zrcher C et al,. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008 65 1655-1658
13. Kappos L, Gold R, Knstler E. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology 1990 40 S261
14. Kingwell E, Koch M, Leung B et al,. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010 74 1-5
15. Kremer LCM, Bastiaansen BAJ, Offringa M et al,. Troponin T in the first 24h after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002 38 686-689 (Pubitemid 34251392)
16. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007 68 S7-S12 (Pubitemid 46626001)
17. Kuntz NL, Chabas D, Weinstock-Guttman B et al,. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 2010 11 505-520
18. Kurztke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 1444-1452
19. Makhani N, Gorman MP, Branson HM et al,. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009 72 2076-2082
20. Marriott JJ, Miyasaki JM, Gronseth G et al,. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010 74 1463-1470
21. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008 358 647-648 (Pubitemid 351214309)
22. Multiple sclerosis therapy consensus group (MSTCG),. Wiendl H, Toyka K, Rieckmann P et al,. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008 255 1449-63
23. Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Therap 2006 109 198-209 (Pubitemid 41740821)
24. Ness JM, Chabas D, Sadovnick AD. etal International pediatric MS study group Clinical features of children and adolescents with multiple sclerosis. Neurology 2007 68 S37-S45 (Pubitemid 46626004)
25. Pascual AM, Téllez N, Bosc I et al,. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009 15 1303-1310
26. Pattoneri P, Sozzi F, Pela G et al,. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis. Echocardiography 2009 26 397-402
27. Pohl D, Waubant E, Banwell B et al,. International pediatric MS study group. Treatment of pediatric multiple sclerosis and variants. Neurology 2007 68 S54-S65 (Pubitemid 46626006)
28. Polman CH, OConnor PW, Havrdova E et al,. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 899-910
29. Ramtahal J, Jacob A, Das K et al,. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing-remitting multiple sclerosis. J Neurol 2006 253 1160-1164 (Pubitemid 44511472)
30. Renoux C, Vukusic S, Mikaeloff Y. etal for the Adult Neurology Departments KIDMUS Study Group Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 356 2603-2613 (Pubitemid 46961005)
31. Rieckmann P, Toyka KV, Bassetti C. etal Multiple Sclerosis Therapy Consensus Group (MSTCG) Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 2004 251 1329-1339
32. Shenkenberg TD, van Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986 105 76-81 [Review]
33. Simone IL, Carrara D, Tortorella C et al,. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002 59 1922-1928 (Pubitemid 36076565)
34. Steinherz LJ, Graham T, Hurwitz R et al,. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer study Group. Pediatrics 1992 89 942-949
35. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 619 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995 24 352-361
36. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE- 4.02-2009-09-15-QuickReference-8.5x11.pdf Accessed May 14 2010
37. Van Dalen EC, van der Pal HJH, Bakker PJM et al,. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004 40 463-652
38. Van Dalen EC, van der Pal HJH, Kok WEM et al,. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 2006 42 3191-3189
39. Weinshenker BG, OBrien PC, Petterson TM et al,. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999 46 878-886
40. West TW, Cree TA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010 68 395-399